Cancer testis antigen MAGEA3 in serum and serum-derived exosomes serves as a promising biomarker in lung adenocarcinoma
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Melanoma Antigen Gene A3 (MAGEA3) is upregulated in lung adenocarcinoma (LUAD) patients' serum and exosomes. MAGEA3 shows diagnostic potential as a biomarker for LUAD and may serve as an immunotherapy target.
Area Of Science
- Oncology
- Molecular Biology
- Immunology
Background
- Cancer testis antigens (CTAs) like Melanoma Antigen Gene A3 (MAGEA3) are implicated in various cancers.
- The expression of MAGEA3 in the serum of lung adenocarcinoma (LUAD) patients is not well-characterized.
Purpose Of The Study
- To investigate the expression pattern of MAGEA3 and MAGEA4 in the serum and serum exosomes of LUAD patients.
- To evaluate the diagnostic value of MAGEA3 and MAGEA4 as biomarkers for LUAD.
- To explore the correlation between MAGEA3 expression and tumor microenvironment, including immune cell infiltration.
Main Methods
- Quantitative real-time PCR (qRT-PCR) for mRNA expression of MAGEA3 and MAGEA4.
- Enzyme-linked immunosorbent assay (ELISA) for protein expression of MAGEA3 and MAGEA4.
- Receiver Operating Characteristic (ROC) curve analysis to assess diagnostic value.
- Bioinformatic analysis (TIMER, CIBERSORT, TISIDB) to correlate MAGEA3 with immune cells.
Main Results
- Serum and exosome MAGEA3 and MAGEA4 mRNA levels were significantly higher in LUAD patients compared to healthy donors.
- Serum MAGEA3 mRNA and protein levels were elevated in LUAD patients and correlated with clinicopathologic parameters (tumor diameter, TNM stage, NSE).
- MAGEA3 mRNA showed significant diagnostic value in serum (AUC=0.781) and serum-derived exosomes (AUC=0.832).
- MAGEA3 mRNA expression correlated positively with neutrophils, M2 macrophages, resting dendritic cells, and eosinophils, but negatively with lymphocytes and other immune cells.
Conclusions
- MAGEA3 mRNA and protein are upregulated in LUAD patients.
- MAGEA3 serves as a potential diagnostic biomarker for LUAD.
- MAGEA3 represents a promising target for LUAD immunotherapy.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
